Compounds > technetium tc 99m pentetate
Page last updated: 2024-09-05

technetium tc 99m pentetate and Adverse Drug Event

technetium tc 99m pentetate has been researched along with Adverse Drug Event in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calcagni, ML; Franceschini, R; Fuso, L; Giordano, A; Pistelli, R; Rossi, B; Rufini, V; Troncone, L; Valente, S1

Other Studies

1 other study(ies) available for technetium tc 99m pentetate and Adverse Drug Event

ArticleYear
Use of metaiodobenzylguanidine (MIBG) in pneumology.
    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1995, Volume: 39, Issue:4 Suppl 1

    Topics: 3-Iodobenzylguanidine; Adrenergic Fibers; Adult; Aerosols; Animals; Biomarkers; Bronchi; Chromatography; Drug-Related Side Effects and Adverse Reactions; Endothelium, Vascular; Feasibility Studies; Humans; Injections, Intravenous; Iodine Radioisotopes; Iodobenzenes; Lung; Lung Diseases; Metabolic Clearance Rate; Nerve Endings; Norepinephrine; Pulmonary Fibrosis; Radionuclide Imaging; Radiopharmaceuticals; Respiratory Distress Syndrome; Technetium Tc 99m Pentetate

1995